89445-80-7

Usage

Uses

Used in Pharmaceutical Research and Development:
OTAVA-BB BB7020204772 is used as a compound in drug discovery for its potential pharmacological or biochemical properties. It is likely to undergo testing and evaluation in a laboratory setting to determine its efficacy and safety for possible therapeutic applications.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, OTAVA-BB BB7020204772 serves as a valuable component for the design and synthesis of new drugs. Its unique structure and properties may contribute to the development of innovative therapeutic agents that address unmet medical needs.
Used in Drug Discovery Databases:
OTAVA-BB BB7020204772 is also utilized as a part of extensive databases of chemical compounds. These databases are crucial for researchers to access a wide range of molecules for screening and further exploration in the quest to find new drugs and treatments for various diseases and conditions.

InChI:InChI=1/C11H10ClNO/c1-7-6-10(12)13-11-8(7)4-3-5-9(11)14-2/h3-6H,1-2H3

Upstream product

• 30198-01-7 8-methoxy-4-methyl-1H-quinolin-2-one 
• 30198-01-7 8-methoxy-4-methyl-quinolin-2-ol 

Relevant academic research and scientific papers

A study of antibacterial activity of some novel 8-methoxy-4-methyl- quinoline derivatives

In the present study, some quinoline derivatives have been synthesized like8-methoxy-4-methyl-2-amino-(3'-chloro-2'-oxo-4'-substituted aryl-1'-azetidinyl)quinolines 8-12 and 8-methoxy-4-methyl-2-amino-(2'- substituted aryl-4'-oxo-1',3'-thiazolidin-3'-yl)

THERAPEUTIC AGENTS I

Compounds of formula(I), processes for preparing such compounds, their use in the treatment of obesity, psychiatric disorders, cognitive disorders, memory disorders, schizophrenia, epilepsy, and related conditions, and neurological disorders such as dementia, multiple sclerosis, Parkinson's disease, Huntington's chorea and Alzheimer's disease and pain related disorders, and pharmaceutical compositions containing them.

2,4-Diamino-5-benzylpyrimidines and analogues as antibacterial agents. 10. 2,4-Diamino-5-(6-quinolylmethyl)- and -[(tetrahydro-6-quinolyl)methyl]pyrimidine derivatives. Further specificity studies

A series of 18 2,4-diamino-5-[(1,2,3,4-tetrahydro-6-quinolyl)methyl]pyrimidines has been prepared by the condensation of 2,4-diamino-5-(hydroxymethyl)pyrimidine with 1,2,3,4-tetrahydroquinolines in acidic medium. Several derivatives were catalytically aromatized; others were synthesized from these by routine aromatic substitution or by condensations of (anilinomethyl)pyrimidines to give quinolinylmethyl analogues. Compounds with 4-methyl-8-methoxy substitution are closely related to trimethoprim (1a) in structure and are excellent inhibitors of bacterial dihydrofolate reductase, with activity at least equivalent to that of 1a. The highest degree of inhibition was achieved with the rigid aromatic series, but greater specificity was accomplished among the tetrahydroquinoline derivatives. This was directly related to N-1 substitution of 4-methyl-8-methoxy derivatives. The spatial relationships around N-1 and protonation at this site may both affect selectivity. Such compounds also had excellent broad-spectrum in vitro antibacterial activity.

2,4-diamino-5-(1,2,3,4-tetrahydro-(substituted or unsubstituted)-6-quinolylmethyl)pyrimidines, useful as antimicrobials

Compounds of the formula (II) STR1 or a salt, N-oxide or acyl derivative thereof, wherein Y is a group STR2 which is optionaly substituted and which optionally contain a nitrogen atom at one of positions A, B, C, D or E, in which the dotted line represents aromatic rings unless one of the rings contains a nitrogen atom in which case this ring is either aromatic or partially saturated, have antimicrobial properties. Processes for making these compounds, pharmaceutical compositions containing them and the medical use of the compounds are also disclosed.